American Society of Clinical Oncology (ASCO)
Journal of Clinical Oncology
,  volume 41 ,  issue 7 ,  pages 1470-1491

Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline

Manish N. Shah 1
, 
Erin B. Kennedy 2
, 
Ashley E Alarcon Rozas 3
, 
Thierry Alcindor 4
, 
Angela N. Bartley 5
, 
Aubrey Belk Malowany 6
, 
Nishin A. Bhadkamkar 7
, 
Dana Deighton 8
, 
Yelena Y. Janjigian 9
, 
Asha Karippot 10
, 
Uqba Khan 1
, 
Daniel A. King 11
, 
Kelsey Klute 12
, 
Jill Lacy 13
, 
James J. Lee 14
, 
Rutika Mehta 15
, 
Sarbajit Mukherjee 16
, 
Arun Nagarajan 17
, 
Haeseong Park 18
, 
Anwaar Saeed 19
, 
Thomas J. Semrad 20
, 
Kohei Shitara 21
, 
Elizabeth Smyth 22
, 
Nataliya V. Uboha 23
, 
Melani Vincelli 24
, 
Zev Wainberg 25
, 
Lakshmi Rajdev 26
1
 
2
 
American Society of Clinical Oncology, Alexandria, VA
3
 
Clinica Santa Beatriz, Lima, Peru | 
4
 
5
 
St Joseph Mercy Hospital, Ann Arbor, MI | 
6
 
DeGregorio Family Foundation, Pleasantville, NY | 
7
 
8
 
Esophageal Cancer Action Network, Stevenson, MD
9
 
10
 
Texas Oncology, Plano, TX | 
11
 
Northwell Health, New Hyde Park, NY | 
12
 
13
 
14
 
Broome Oncology Ltd, Binghamton, NY
15
 
16
 
Roswell Park Comprehensive Cancer Center, buffalo, NY | 
17
 
18
 
19
 
20
 
Gene Upshaw Memorial Tahoe Forest Cancer Center, Truckee, CA | 
21
 
National Cancer Center East, Kashiwa, Japan | 
22
 
23
 
24
 
Debbie's Dream Foundation, Plantation, FL | 
25
 
26
 
Northwell Health, New York, NY | 
Publication type: Journal Article
Publication date: 2023-03-01
American Society of Clinical Oncology (ASCO)
scimago Q1
wos Q1
SJR: 11.205
CiteScore: 38.9
Impact factor: 41.9
ISSN: 0732183X, 15277755
DOI:  10.1200/jco.22.02331
PubMed ID:  36603169
Cancer Research
Oncology
Abstract
PURPOSE

To develop recommendations involving targeted therapies for patients with advanced gastroesophageal cancer.

METHODS

The American Society of Clinical Oncology convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice.

RESULTS

Eighteen randomized controlled trials met the inclusion criteria for the systematic review.

RECOMMENDATIONS

For human epidermal growth factor receptor 2 (HER2)–negative patients with gastric adenocarcinoma (AC) and programmed death-ligand 1 (PD-L1) combined positive score (CPS) ≥ 5, first-line therapy with nivolumab and chemotherapy (CT) is recommended. For HER2-negative patients with esophageal or gastroesophageal junction (GEJ) AC and PD-L1 CPS ≥ 5, first-line therapy with nivolumab and CT is recommended. First-line therapy with pembrolizumab and CT is recommended for HER2-negative patients with esophageal or GEJ AC and PD-L1 CPS ≥ 10. For patients with esophageal squamous cell carcinoma and PD-L1 tumor proportion score ≥ 1%, nivolumab plus CT, or nivolumab plus ipilimumab is recommended; for patients with esophageal squamous cell carcinoma and PD-L1 CPS ≥ 10, pembrolizumab plus CT is recommended. For patients with HER2-positive gastric or GEJ previously untreated, unresectable or metastatic AC, trastuzumab plus pembrolizumab is recommended, in combination with CT. For patients with advanced gastroesophageal or GEJ AC whose disease has progressed after first-line therapy, ramucirumab plus paclitaxel is recommended. For HER2-positive patients with gastric or GEJ AC who have progressed after first-line therapy, trastuzumab deruxtecan is recommended. In all cases, participation in a clinical trial is recommended as it is the panel's expectation that targeted treatment options for gastroesophageal cancer will continue to evolve. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .

Found 
Found 

Top-30

Journals

1
2
3
4
5
6
Frontiers in Oncology
Frontiers in Oncology, 6, 3.92%
Frontiers in Oncology
6 publications, 3.92%
Frontiers in Immunology
Frontiers in Immunology, 5, 3.27%
Frontiers in Immunology
5 publications, 3.27%
Cancers
Cancers, 4, 2.61%
Cancers
4 publications, 2.61%
Frontiers in Pharmacology
Frontiers in Pharmacology, 3, 1.96%
Frontiers in Pharmacology
3 publications, 1.96%
World Journal of Gastroenterology
World Journal of Gastroenterology, 3, 1.96%
World Journal of Gastroenterology
3 publications, 1.96%
The Lancet Oncology
The Lancet Oncology, 3, 1.96%
The Lancet Oncology
3 publications, 1.96%
Modern Pathology
Modern Pathology, 3, 1.96%
Modern Pathology
3 publications, 1.96%
ESMO Open
ESMO Open, 3, 1.96%
ESMO Open
3 publications, 1.96%
International Journal of Molecular Sciences
International Journal of Molecular Sciences, 2, 1.31%
International Journal of Molecular Sciences
2 publications, 1.31%
Clinical Cancer Research
Clinical Cancer Research, 2, 1.31%
Clinical Cancer Research
2 publications, 1.31%
Current Oncology
Current Oncology, 2, 1.31%
Current Oncology
2 publications, 1.31%
ESMO Gastrointestinal Oncology
ESMO Gastrointestinal Oncology, 2, 1.31%
ESMO Gastrointestinal Oncology
2 publications, 1.31%
Cell Death and Disease
Cell Death and Disease, 2, 1.31%
Cell Death and Disease
2 publications, 1.31%
BMC Cancer
BMC Cancer, 2, 1.31%
BMC Cancer
2 publications, 1.31%
Aging
Aging, 2, 1.31%
Aging
2 publications, 1.31%
World Journal of Gastrointestinal Oncology
World Journal of Gastrointestinal Oncology, 2, 1.31%
World Journal of Gastrointestinal Oncology
2 publications, 1.31%
Critical Reviews in Oncology/Hematology
Critical Reviews in Oncology/Hematology, 2, 1.31%
Critical Reviews in Oncology/Hematology
2 publications, 1.31%
Gastric Cancer
Gastric Cancer, 2, 1.31%
Gastric Cancer
2 publications, 1.31%
Academic Radiology
Academic Radiology, 2, 1.31%
Academic Radiology
2 publications, 1.31%
Clinical Oncology
Clinical Oncology, 2, 1.31%
Clinical Oncology
2 publications, 1.31%
Surgical Endoscopy and Other Interventional Techniques
Surgical Endoscopy and Other Interventional Techniques, 2, 1.31%
Surgical Endoscopy and Other Interventional Techniques
2 publications, 1.31%
BMJ Open
BMJ Open, 2, 1.31%
BMJ Open
2 publications, 1.31%
Journal of Gastrointestinal Cancer
Journal of Gastrointestinal Cancer, 2, 1.31%
Journal of Gastrointestinal Cancer
2 publications, 1.31%
Immunotherapy
Immunotherapy, 2, 1.31%
Immunotherapy
2 publications, 1.31%
Discover Oncology
Discover Oncology, 2, 1.31%
Discover Oncology
2 publications, 1.31%
The Lancet
The Lancet, 1, 0.65%
The Lancet
1 publication, 0.65%
Nature Reviews Clinical Oncology
Nature Reviews Clinical Oncology, 1, 0.65%
Nature Reviews Clinical Oncology
1 publication, 0.65%
Biomolecules
Biomolecules, 1, 0.65%
Biomolecules
1 publication, 0.65%
American Journal of Pathology
American Journal of Pathology, 1, 0.65%
American Journal of Pathology
1 publication, 0.65%
1
2
3
4
5
6

Publishers

5
10
15
20
25
30
35
40
Springer Nature
Springer Nature, 37, 24.18%
Springer Nature
37 publications, 24.18%
Elsevier
Elsevier, 36, 23.53%
Elsevier
36 publications, 23.53%
Frontiers Media S.A.
Frontiers Media S.A., 15, 9.8%
Frontiers Media S.A.
15 publications, 9.8%
MDPI
MDPI, 14, 9.15%
MDPI
14 publications, 9.15%
Wiley
Wiley, 8, 5.23%
Wiley
8 publications, 5.23%
Taylor & Francis
Taylor & Francis, 8, 5.23%
Taylor & Francis
8 publications, 5.23%
Baishideng Publishing Group
Baishideng Publishing Group, 5, 3.27%
Baishideng Publishing Group
5 publications, 3.27%
American Society of Clinical Oncology (ASCO)
American Society of Clinical Oncology (ASCO), 4, 2.61%
American Society of Clinical Oncology (ASCO)
4 publications, 2.61%
AME Publishing Company
AME Publishing Company, 4, 2.61%
AME Publishing Company
4 publications, 2.61%
BMJ
BMJ, 3, 1.96%
BMJ
3 publications, 1.96%
Cold Spring Harbor Laboratory
Cold Spring Harbor Laboratory, 2, 1.31%
Cold Spring Harbor Laboratory
2 publications, 1.31%
American Association for Cancer Research (AACR)
American Association for Cancer Research (AACR), 2, 1.31%
American Association for Cancer Research (AACR)
2 publications, 1.31%
S. Karger AG
S. Karger AG, 2, 1.31%
S. Karger AG
2 publications, 1.31%
Impact Journals
Impact Journals, 2, 1.31%
Impact Journals
2 publications, 1.31%
SAGE
SAGE, 2, 1.31%
SAGE
2 publications, 1.31%
XMLink, 1, 0.65%
XMLink
1 publication, 0.65%
American Medical Association (AMA)
American Medical Association (AMA), 1, 0.65%
American Medical Association (AMA)
1 publication, 0.65%
Public Library of Science (PLoS)
Public Library of Science (PLoS), 1, 0.65%
Public Library of Science (PLoS)
1 publication, 0.65%
Research Square Platform LLC, 1, 0.65%
Research Square Platform LLC
1 publication, 0.65%
Oxford University Press
Oxford University Press, 1, 0.65%
Oxford University Press
1 publication, 0.65%
Georg Thieme Verlag KG
Georg Thieme Verlag KG, 1, 0.65%
Georg Thieme Verlag KG
1 publication, 0.65%
Remedium, Ltd.
Remedium, Ltd., 1, 0.65%
Remedium, Ltd.
1 publication, 0.65%
Bentham Science Publishers Ltd.
Bentham Science Publishers Ltd., 1, 0.65%
Bentham Science Publishers Ltd.
1 publication, 0.65%
5
10
15
20
25
30
35
40
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
153
Share
Cite this
GOST |
Cite this
GOST Copy
Shah M. N. et al. Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline // Journal of Clinical Oncology. 2023. Vol. 41. No. 7. pp. 1470-1491.
GOST all authors (up to 50) Copy
Shah M. N., Kennedy E. B., Alarcon Rozas A. E., Alcindor T., Bartley A. N., Malowany A. B., Bhadkamkar N. A., Deighton D., Janjigian Y. Y., Karippot A., Khan U., King D. A., Klute K., Lacy J., Lee J. J., Mehta R., Mukherjee S., Nagarajan A., Park H., Saeed A., Semrad T. J., Shitara K., Smyth E., Uboha N. V., Vincelli M., Wainberg Z., Rajdev L. Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline // Journal of Clinical Oncology. 2023. Vol. 41. No. 7. pp. 1470-1491.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1200/jco.22.02331
UR - https://doi.org/10.1200/jco.22.02331
TI - Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline
T2 - Journal of Clinical Oncology
AU - Shah, Manish N.
AU - Kennedy, Erin B.
AU - Alarcon Rozas, Ashley E
AU - Alcindor, Thierry
AU - Bartley, Angela N.
AU - Malowany, Aubrey Belk
AU - Bhadkamkar, Nishin A.
AU - Deighton, Dana
AU - Janjigian, Yelena Y.
AU - Karippot, Asha
AU - Khan, Uqba
AU - King, Daniel A.
AU - Klute, Kelsey
AU - Lacy, Jill
AU - Lee, James J.
AU - Mehta, Rutika
AU - Mukherjee, Sarbajit
AU - Nagarajan, Arun
AU - Park, Haeseong
AU - Saeed, Anwaar
AU - Semrad, Thomas J.
AU - Shitara, Kohei
AU - Smyth, Elizabeth
AU - Uboha, Nataliya V.
AU - Vincelli, Melani
AU - Wainberg, Zev
AU - Rajdev, Lakshmi
PY - 2023
DA - 2023/03/01
PB - American Society of Clinical Oncology (ASCO)
SP - 1470-1491
IS - 7
VL - 41
PMID - 36603169
SN - 0732-183X
SN - 1527-7755
ER -
BibTex |
Cite this
BibTex (up to 50 authors) Copy
@article{2023_Shah,
author = {Manish N. Shah and Erin B. Kennedy and Ashley E Alarcon Rozas and Thierry Alcindor and Angela N. Bartley and Aubrey Belk Malowany and Nishin A. Bhadkamkar and Dana Deighton and Yelena Y. Janjigian and Asha Karippot and Uqba Khan and Daniel A. King and Kelsey Klute and Jill Lacy and James J. Lee and Rutika Mehta and Sarbajit Mukherjee and Arun Nagarajan and Haeseong Park and Anwaar Saeed and Thomas J. Semrad and Kohei Shitara and Elizabeth Smyth and Nataliya V. Uboha and Melani Vincelli and Zev Wainberg and Lakshmi Rajdev},
title = {Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
publisher = {American Society of Clinical Oncology (ASCO)},
month = {mar},
url = {https://doi.org/10.1200/jco.22.02331},
number = {7},
pages = {1470--1491},
doi = {10.1200/jco.22.02331}
}
MLA
Cite this
MLA Copy
Shah, Manish N., et al. “Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.” Journal of Clinical Oncology, vol. 41, no. 7, Mar. 2023, pp. 1470-1491. https://doi.org/10.1200/jco.22.02331.
Profiles